The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size when administered by posterior juxtascleral depot (PJD) every 3 months (AA 15 mg) or 6 months (AA 15 mg, AA 30 mg) in patients with exudative age-related macular degeneration (AMD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
240
One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
One 0.5 mL sham injection at 6 month intervals
Alcon Study Sites
Fort Worth, Texas, United States
Mean change in best-corrected visual acuity (BCVA) at Month 12 from baseline
Time frame: Month 12
Mean change in lesion growth at Month 12 from baseline
Time frame: Month 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.